- Home
- SENEA vs TYRA Comparison
SENEA vs TYRA Comparison
Compare SENEA & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- TYRA
- Stock Information
- Founded
- SENEA 1949
- TYRA 2018
- Country
- SENEA United States
- TYRA United States
- Employees
- SENEA N/A
- TYRA N/A
- Industry
- SENEA Packaged Foods
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- TYRA Health Care
- Exchange
- SENEA Nasdaq
- TYRA Nasdaq
- Market Cap
- SENEA 557.7M
- TYRA 666.4M
- IPO Year
- SENEA N/A
- TYRA 2021
- Fundamental
- Price
- SENEA $80.49
- TYRA $13.17
- Analyst Decision
- SENEA
- TYRA Strong Buy
- Analyst Count
- SENEA 0
- TYRA 6
- Target Price
- SENEA N/A
- TYRA $30.50
- AVG Volume (30 Days)
- SENEA 13.7K
- TYRA 254.2K
- Earning Date
- SENEA 02-06-2025
- TYRA 03-18-2025
- Dividend Yield
- SENEA N/A
- TYRA N/A
- EPS Growth
- SENEA 25.61
- TYRA N/A
- EPS
- SENEA 5.45
- TYRA N/A
- Revenue
- SENEA $1,541,031,000.00
- TYRA N/A
- Revenue This Year
- SENEA N/A
- TYRA N/A
- Revenue Next Year
- SENEA N/A
- TYRA N/A
- P/E Ratio
- SENEA $14.77
- TYRA N/A
- Revenue Growth
- SENEA 4.01
- TYRA N/A
- 52 Week Low
- SENEA $46.56
- TYRA $11.89
- 52 Week High
- SENEA $81.45
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- SENEA 65.40
- TYRA 43.64
- Support Level
- SENEA $77.08
- TYRA $12.27
- Resistance Level
- SENEA $81.45
- TYRA $13.79
- Average True Range (ATR)
- SENEA 2.00
- TYRA 0.71
- MACD
- SENEA 0.54
- TYRA 0.03
- Stochastic Oscillator
- SENEA 90.83
- TYRA 51.09
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).